Journal of Chemotherapy最新文献_第6页

Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells. Cinobufagin调节microRNA-149-3p/AFF4轴影响顺铂耐药卵巢癌细胞的增殖和凋亡。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-05-27 DOI: 10.1080/1120009X.2025.2508614

Yunfei Liu, Taoli Chen, Yanpeng Wang, Yuanyuan Gao, Ning Xie, Wanping Xia, Qichuan Wang

{"title":"Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells.","authors":"Yunfei Liu, Taoli Chen, Yanpeng Wang, Yuanyuan Gao, Ning Xie, Wanping Xia, Qichuan Wang","doi":"10.1080/1120009X.2025.2508614","DOIUrl":"10.1080/1120009X.2025.2508614","url":null,"abstract":"Although cinobufagin has been demonstrated to inhibit the growth of various malignant tumors, its functional role in ovarian cancer remains unclear. In light of this, the present study aims to thoroughly investigate the effects of cinobufagin on ovarian cancer progression and elucidate its underlying molecular mechanisms, thereby providing novel insights into future therapeutic strategies. A2780/DDP, a cisplatin-resistant cell line for ovarian cancer, was treated with gradient doses of cinobufagin. The microRNA-149-3p and AFF4 binding sites were predicted by bioinformatics. In cisplatin-resistant ovarian cancer cells, microRNA-149-3p and AFF4 expression were detected using qRT-PCR, and the binding association between microRNA-149-3p and AFF4 was confirmed by dual-luciferase and RIP assays. Cell viability was assessed using the CCK-8 test, cell proliferation was identified using the EdU assay and colony formation, and cell apoptosis was identified using flow cytometry. The results showed that cinobufagin inhibited the proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. microRNA-149-3p was highly expressed in cisplatin-resistant ovarian cancer cells, while AFF4 was lowly expressed in these cells. Overexpression of microRNA-149-3p promoted the proliferation and inhibited the apoptosis of cisplatin-resistant ovarian cancer cells, which was reversed by the addition of cinobufagin. Overexpression of AFF4 suppressed proliferation and promoted apoptosis of cisplatin-resistant ovarian cancer cells. MicroRNA-149-3p repressed AFF4 expression, and partial attenuation of the effects of AFF4 overexpression on cell phenotype was observed when microRNA-149-3p was overexpressed. In conclusion,cinobufagin regulated microRNA-149-3p/AFF4 axis to inhibit proliferation of ovarian cancer cells and promote cell apoptosis. Targeting the microRNA-149-3p/AFF4 axis with cinobufagin could represent a novel therapeutic strategy for ovarian cancer.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"345-354"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of pembrolizumab in patients with chemotherapy-resistant gestational trophoblastic neoplasia, a case report. 派姆单抗治疗化疗耐药妊娠滋养细胞瘤的疗效，1例报告。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-05-29 DOI: 10.1080/1120009X.2025.2512262

Sercan Ön

引用次数: 0

Recent advances in polymer-based nanoparticles: current strategies and translational challenges in cancer therapy. 聚合物基纳米颗粒的最新进展：癌症治疗的当前策略和转化挑战。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-11-01 DOI: 10.1080/1120009X.2025.2573516

Kumar Janakiraman, Vaidevi Sethuraman, Venkateshwaran Krishnaswami, Geethanjali Sampath

{"title":"Recent advances in polymer-based nanoparticles: current strategies and translational challenges in cancer therapy.","authors":"Kumar Janakiraman, Vaidevi Sethuraman, Venkateshwaran Krishnaswami, Geethanjali Sampath","doi":"10.1080/1120009X.2025.2573516","DOIUrl":"10.1080/1120009X.2025.2573516","url":null,"abstract":"Polymer-based nanoparticles (PNPs) are emerging as a cornerstone in cancer therapy due to their ability to enhance drug solubility, improve pharmacokinetics and achieve precise tumor targeting. Nanoparticles, encompassing liposomes, dendrimers, and metallic particles, include typical characteristics such as improved surface area, regulated release and the capacity to encapsulate diverse therapeutic compounds augmenting the pharmacokinetics and bioavailability of anticancer drugs. Recent studies demonstrate drug loading efficiencies of 80-90%, circulation half-life extensions of 2-5 fold, and tumor accumulation improvements of 3-10 times compared to free drugs. FDA-approved formulations such as Abraxane® (albumin-bound paclitaxel) and clinical candidates like Genexol-PM® (polymeric micelles) highlight the translational relevance of PNPs. This review consolidates advancements in polymeric nanocarriers, including nanospheres, nano-capsules and hybrid composites, while addressing limitations in regulatory approval and personalized oncology integration. This study shows that nanoparticle-based cancer therapeutics hold immense potential to improve treatment efficacy and patient outcomes in clinical oncology.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"321-342"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer. 多司达单抗联合化疗与派姆单抗联合化疗作为转移性非鳞状非小细胞肺癌一线治疗的成本-效果分析

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-07-01 Epub Date: 2025-06-28 DOI: 10.1080/1120009X.2025.2524906

Tong Liu, Xin Zhang, Bingjie Liu, Yao Yao, Ruihong Yao, Zhiqiang Tong, Xue Teng, Mei Dong, Lu Zhong

{"title":"Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.","authors":"Tong Liu, Xin Zhang, Bingjie Liu, Yao Yao, Ruihong Yao, Zhiqiang Tong, Xue Teng, Mei Dong, Lu Zhong","doi":"10.1080/1120009X.2025.2524906","DOIUrl":"10.1080/1120009X.2025.2524906","url":null,"abstract":"Lung cancer is one of the most common malignant cancers in most countries, and non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Checkpoint inhibitor immunotherapy is the preferred therapy for metastatic NSCLC patients who do not exhibit EGFR exon 19 deletion or L858R or ALK, RET, or ROS1 rearrangements. A recent clinical study (PERLA, NCT04581824) reports that dostarlimab has comparable effectiveness to pembrolizumab and presents clinical reliability as a first-line treatment for patients with metastatic non-squamous NSCLC. Our study employed a partitioned survival model (PSM) to evaluate the cost-effectiveness of dostarlimab plus chemotherapy compared to pembrolizumab plus chemotherapy as a first-line treatment of metastatic NSCLC from the perspective of healthcare payers in China. We found that when the time horizon was 10 years, dostarlimab plus chemotherapy was not cost-effective at the willingness to pay (WTP) threshold of 287,247 Chinese yuan (CNY)/QALY (35,057 EUR/QALY at an exchange rate of 1 CNY = 0.122 EUR).","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"389-398"},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Eravacycline in sepsis complicated by Clostridioides difficile infection: a brief case series. 依拉瓦环素治疗脓毒症合并艰难梭菌感染：一个简短的病例系列。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-06-16 DOI: 10.1080/1120009X.2026.2684333

Federico Giovagnorio, Giovanni Del Fabro, Agnese Zanus-Fortes, Camilla Negri, Astrid Callegari, Chiara Zanusso, Barbara Basso, Silvia Grazioli, Marta Del Pup, Ada Zanier, Viviana Castaldo, Ingrid Reffo, Sergio Venturini

{"title":"Eravacycline in sepsis complicated by Clostridioides difficile infection: a brief case series.","authors":"Federico Giovagnorio, Giovanni Del Fabro, Agnese Zanus-Fortes, Camilla Negri, Astrid Callegari, Chiara Zanusso, Barbara Basso, Silvia Grazioli, Marta Del Pup, Ada Zanier, Viviana Castaldo, Ingrid Reffo, Sergio Venturini","doi":"10.1080/1120009X.2026.2684333","DOIUrl":"10.1080/1120009X.2026.2684333","url":null,"abstract":"Clostridioides difficile infection complicating severe bacterial infections presents a therapeutic challenge, when antimicrobial discontinuation is unfeasible. Eravacycline, a synthetic fluorocycline with broad-spectrum activity against Gram-positive, Gram-negative and anaerobic bacteria, including C. difficile, carries a relatively low risk of inducing C. difficile. Although approved for complicated intra-abdominal infections, emerging evidence indicates its potential for other severe infections. We report three cases of C. difficile infection during systemic antibacterial therapy for severe infections complicated by sepsis. In all cases, antibiotics could not be discontinued due to uncontrolled infection. Switching to intravenous eravacycline, alongside C. difficile-directed therapy, allowed clinical improvement of the underlying infection and resolution of diarrhea, with no eravacycline-related adverse events. Two patients survived to discharge without recurrence at 90-day follow-up, whereas one patient died from unrelated complications. This limited experience indicates that eravacycline might be a microbiome-sparing stewardship option in selected severe infections complicated by C. difficile infection.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-5"},"PeriodicalIF":2.1,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study. 阿帕替尼联合卡培他滨+替莫唑胺与舒尼替尼治疗晚期胃肠胰腺神经内分泌肿瘤：一项倾向评分匹配的现实世界研究。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-06-12 DOI: 10.1080/1120009X.2026.2684301

Tiegang Li

{"title":"Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.","authors":"Tiegang Li","doi":"10.1080/1120009X.2026.2684301","DOIUrl":"10.1080/1120009X.2026.2684301","url":null,"abstract":"Apatinib combined with CAPTEM (capecitabine plus temozolomide) has demonstrated preliminary activity in neuroendocrine tumours, yet head-to-head comparative efficacy data against standard-of-care sunitinib remain lacking. This study aims to evaluate the efficacy and safety of both regimens in advanced GEP-NETs using real-world data. This retrospective analysis examined patients with advanced GEP-NETs treated with either apatinib plus CAPTEM or sunitinib.Baseline characteristics (e.g. pathological grade, hepatic tumour burden) were balanced between groups using 1:1 propensity score matching (PSM). The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. A total of 150 patients were included in the analysis, with 52 patients in each group after PSM. Following matching, the median PFS was significantly longer in the apatinib plus CAPTEM group compared with the sunitinib group (not reached [NR] [95% CI: 36.6-NR] vs 17.9 months [95% CI: 8.0-18.0]; hazard ratio [HR] = 0.17, 95% CI: 0.08-0.36; p < 0.001). The combination therapy group also demonstrated a significant OS benefit (52.0 months [95% CI: 48.1-58.0] vs 16.4 months [95% CI: 12.7-22.1]; HR = 0.10, 95% CI: 0.05-0.22; p < 0.001). The ORR was numerically higher in the combination group than in the sunitinib group (65.4% vs 50.0%, p = 0.164). Regarding safety, the sunitinib group exhibited higher rates of hand-foot syndrome and diarrhoea, whilst the combination group did not experience any unexpected severe toxicities. In a PSM-matched cohort of advanced GEP-NETs, apatinib combined with CAPTEM was associated with improved PFS and OS, together with a numerically elevated ORR. Given the retrospective design and the potential for residual confounding, these findings should be considered hypothesis-generating and warrant prospective validation.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review. 中性粒细胞减少性脓毒症抗菌治疗的药代动力学/药效学优化：综合综述。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-06-12 DOI: 10.1080/1120009X.2026.2684308

Bin Qiu, Jianjiang Huang, Fang Zhang, Yuyu Wang

{"title":"Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.","authors":"Bin Qiu, Jianjiang Huang, Fang Zhang, Yuyu Wang","doi":"10.1080/1120009X.2026.2684308","DOIUrl":"10.1080/1120009X.2026.2684308","url":null,"abstract":"Neutropenic sepsis remains a life-threatening complication in patients undergoing cytotoxic chemotherapy or haematopoietic stem cell transplantation. A comprehensive literature search was conducted across PubMed, Embase, and the Cochrane Library through December 2025, focusing on clinical trials, observational studies, and population PK analyses involving neutropenic or febrile neutropenic patients in both adult and paediatric haematology and oncology populations. Pathophysiological changes in neutropenic sepsis-including augmented renal clearance, increased volume of distribution, and hypoalbuminemia-lead to substantial PK variability and frequent target non-attainment with standard dosing. Animal models consistently demonstrate that higher PK/PD targets are required in the absence of neutrophils. PK/PD-guided dose optimisation appears highly beneficial in neutropenic sepsis, although prospective randomised evidence specifically in this population remains limited. Integration of TDM, population PK modelling, and Bayesian dose adaptation into routine clinical practice represents a promising avenue towards improved outcomes, recognising that implementation will depend on locally available laboratory and pharmacy resources.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-29"},"PeriodicalIF":2.1,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148239491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cefiderocol for Stenotrophomonas maltophilia infections: real-world evidence from a multicenter study and a comprehensive literature review. 头孢地罗治疗嗜麦芽窄养单胞菌感染：来自多中心研究和综合文献综述的真实世界证据。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-06-12 DOI: 10.1080/1120009X.2026.2685373

Michela Comi, Giulia Mancarella, Silvia Di Bari, Gianluca Fiorentino, Cosmo Del Borgo, Miriam Lichtner, Claudio Maria Mastroianni, Alessandra Oliva

{"title":"Cefiderocol for Stenotrophomonas maltophilia infections: real-world evidence from a multicenter study and a comprehensive literature review.","authors":"Michela Comi, Giulia Mancarella, Silvia Di Bari, Gianluca Fiorentino, Cosmo Del Borgo, Miriam Lichtner, Claudio Maria Mastroianni, Alessandra Oliva","doi":"10.1080/1120009X.2026.2685373","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2685373","url":null,"abstract":"Stenotrophomonas maltophilia is an opportunistic multidrug-resistant pathogen increasingly associated with severe infections. Although cefiderocol has demonstrated potent in-vitro activity against S. maltophilia, clinical evidence remains limited. We performed a retrospective multicenter study including adult patients with S. maltophilia infections treated with cefiderocol in three tertiary-care hospitals between 2021-2024. Primary outcomes were 30-day mortality, clinical cure, microbiological eradication, and treatment-related adverse events. A review of the available literature was conducted. Fourteen patients were included (median age 61 years; median Charlson Comorbidity Index 5). Pneumonia was the most common infection (50%), while polymicrobial infections occurred in 42.9% of cases. TMP-SMX resistance was observed in 35.7% of isolates. Clinical cure and microbiological eradication were achieved in 64.3% and 75% of patients, respectively, whereas 30-day mortality was 21.4%. No cefiderocol-related adverse events were reported. These findings support cefiderocol as an effective and well-tolerated option for S. maltophilia infections, particularly when conventional therapies are limited.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148225608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome. 通过弹性泵持续大剂量输注哌拉西林/他唑巴坦治疗小儿卡塔格纳综合征：药代动力学目标实现和临床结果

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-06-01 DOI: 10.1080/1120009X.2026.2680734

Marcello Mariani, Sandro Dallorso, Vera Morsellino, Alessio Mesini, Erica Ricci, Carolina Saffioti, Debora Contu, Tommaso Cacco, Alessia Cafaro, Giuliana Cangemi, Elio Castagnola

{"title":"High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.","authors":"Marcello Mariani, Sandro Dallorso, Vera Morsellino, Alessio Mesini, Erica Ricci, Carolina Saffioti, Debora Contu, Tommaso Cacco, Alessia Cafaro, Giuliana Cangemi, Elio Castagnola","doi":"10.1080/1120009X.2026.2680734","DOIUrl":"10.1080/1120009X.2026.2680734","url":null,"abstract":"Multidrug-resistant Achromobacter xylosoxidans infections in pediatric patients with primary ciliary dyskinesia (PCD) often require prolonged intravenous therapy. We evaluated the pharmacokinetics of continuous infusion piperacillin/tazobactam (16 g/2 g daily) in a 13-year-old male with situs inversus and chronic otitis media transitioned from hospital-based electronic infusion to home-based Outpatient Parenteral Antimicrobial Therapy (OPAT) using elastomeric pumps. Plasma concentrations were measured by Therapeutic Drug Monitoring (TDM), and tissue exposure was estimated using conservative penetration coefficients. Drug concentrations consistently remained above the MIC (≤2 mg/L). During hospitalization, steady-state concentrations were stable (27.2-29.0 mg/L; CV 4.5%), whereas during OPAT they were higher and more variable (53.9-80.1 mg/L; CV 20.1%), consistent with the known non-linear delivery profiles of elastomeric devices. Despite this variability, TDM confirmed sustained supratherapeutic exposure, with estimated tissue concentrations remaining >5-fold above the MIC. Clinical resolution was achieved without adverse events, supporting the role of TDM-guided OPAT in difficult-to-treat infections.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapeutic strategies in gastroenteropancreatic neuroendocrine neoplasms: present condition and future developments. 胃肠胰神经内分泌肿瘤的免疫治疗策略：现状和未来发展。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-05-25 DOI: 10.1080/1120009X.2026.2676345

Durlav Chowdhury, Arunava Mishra, Maikala Muskan Rao, Rohan Sahu, Surendra H Bodakhe

{"title":"Immunotherapeutic strategies in gastroenteropancreatic neuroendocrine neoplasms: present condition and future developments.","authors":"Durlav Chowdhury, Arunava Mishra, Maikala Muskan Rao, Rohan Sahu, Surendra H Bodakhe","doi":"10.1080/1120009X.2026.2676345","DOIUrl":"10.1080/1120009X.2026.2676345","url":null,"abstract":"Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous malignancies frequently resistant to standard therapies. Immunotherapy represents a novel management frontier. This review synthesises clinical and translational evidence regarding immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and oncolytic virotherapy in GEP-NENs. We examine critical antigenic targets (somatostatin receptors, DLL3) and strategies to overcome the immunosuppressive tumour immune microenvironment (TIME). While single-agent ICIs show modest efficacy in well-differentiated NETs, dual checkpoint blockade exhibits durable disease control in poorly differentiated NECs. Targeted modalities like DLL3-directed bispecific antibodies demonstrate significant early efficacy. Furthermore, we summarise highly synergistic combinatorial approaches, specifically integrating immunotherapy with anti-angiogenic agents and peptide receptor radionuclide therapy (PRRT). Ongoing biomarker-driven trials and molecular profiling remain essential to optimise patient selection and treatment sequencing.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-17"},"PeriodicalIF":2.1,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148015764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0